FAP and neoplasm: Antibody-based FAP-targeted radiopharmaceuticals like [89Zr]Zr/[177Lu]Lu-AMS002-1-Fc rAb and FAP inhibitor (FAPI) radiopharmaceuticals such as [211At]At/[225Ac]Ac-FAPI-04 and [177Lu]Lu/[225Ac]Ac-FAPI-46 have demonstrated tumor growth suppression in preclinical models 45-47.